Cargando…

Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study

We report the final 2-year end-of-study results from the first clinical trial investigating combination treatment with ruxolitinib and low-dose pegylated interferon-α2 (PEG-IFNα2). The study included 32 patients with polycythemia vera and 18 with primary or secondary myelofibrosis; 46 patients were...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sørensen, Anders Lindholm, Mikkelsen, Stine Ulrik, Knudsen, Trine Alma, Bjørn, Mads Emil, Andersen, Christen Lykkegaard, Bjerrum, Ole Weis, Brochmann, Nana, Patel, Dustin Andersen, Gjerdrum, Lise Mette Rahbek, El Fassi, Daniel, Kruse, Torben A., Larsen, Thomas Stauffer, Mourits-Andersen, Hans Torben, Nielsen, Claus Henrik, Ellervik, Christina, Pallisgaard, Niels, Thomassen, Mads, Kjær, Lasse, Skov, Vibe, Hasselbalch, Hans Carl
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556624/ https://www.ncbi.nlm.nih.gov/pubmed/33054051 http://dx.doi.org/10.3324/haematol.2019.235648

Ejemplares similares

Safety and efficacy of combination therapy of interferon‐α2 and ruxolitinib in polycythemia vera and myelofibrosis
por: Mikkelsen, Stine Ulrik, et al.
Publicado: (2018)

Transcriptional Profiling of Whole Blood Identifies a Unique 5-Gene Signature for Myelofibrosis and Imminent Myelofibrosis Transformation
por: Hasselbalch, Hans Carl, et al.
Publicado: (2014)

Epigenetic changes in myelofibrosis: Distinct methylation changes in the myeloid compartments and in cases with ASXL1 mutations
por: Nielsen, Helene Myrtue, et al.
Publicado: (2017)

Ruxolitinib in Myelofibrosis and Polycythemia Vera
por: Wolfe, Leah
Publicado: (2016)

Publisher Correction: Epigenetic changes in myelofibrosis: Distinct methylation changes in the myeloid compartments and in cases with ASXL1 mutations
por: Nielsen, Helene Myrtue, et al.
Publicado: (2018)

Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms
por: Skov, Vibe, et al.
Publicado: (2022)

Whole Blood Transcriptional Profiling Reveals Deregulation of Oxidative and Antioxidative Defence Genes in Myelofibrosis and Related Neoplasms. Potential Implications of Downregulation of Nrf2 for Genomic Instability and Disease Progression
por: Hasselbalch, Hans Carl, et al.
Publicado: (2014)

The impact of ruxolitinib treatment on inflammation-mediated comorbidities in myelofibrosis and related neoplasms
por: Bjørn, Mads Emil, et al.
Publicado: (2015)

Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
por: Bryan, Jeffrey C., et al.
Publicado: (2016)

Data‐driven analysis of JAK2V617F kinetics during interferon‐alpha2 treatment of patients with polycythemia vera and related neoplasms
por: Pedersen, Rasmus K., et al.
Publicado: (2020)

A 7-Gene Signature Depicts the Biochemical Profile of Early Prefibrotic Myelofibrosis
por: Skov, Vibe, et al.
Publicado: (2016)

Mathematical modelling as a proof of concept for MPNs as a human inflammation model for cancer development
por: Andersen, Morten, et al.
Publicado: (2017)

Ruxolitinib for treatment of polycythemia vera and myelofibrosis in patients after liver transplantation
por: Dold, Leona, et al.
Publicado: (2021)

The gut microbiota in patients with polycythemia vera is distinct from that of healthy controls and varies by treatment
por: Eickhardt-Dalbøge, Christina Schjellerup, et al.
Publicado: (2022)

Revisiting Circulating Extracellular Matrix Fragments as Disease Markers in Myelofibrosis and Related Neoplasms
por: Hasselbalch, Hans Carl, et al.
Publicado: (2023)

Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis
por: Kjær, Lasse, et al.
Publicado: (2023)

Recombinant Interferon-β in the Treatment of Polycythemia Vera and Related Neoplasms: Rationales and Perspectives
por: Hasselbalch, Hans, et al.
Publicado: (2022)

Tumor Lysis Syndrome after the Administration of Ruxolitinib in a Patient with Post-polycythemia Vera Myelofibrosis
por: Koshiishi, Megumi, et al.
Publicado: (2017)

Combination therapy with interferon and ruxolitinib for polycythemia vera and myelofibrosis: are two drugs better than one?
por: Silver, Richard T.
Publicado: (2020)

The Danish National Chronic Myeloid Neoplasia Registry
por: Bak, Marie, et al.
Publicado: (2016)

Association of the blood eosinophil count with end-organ symptoms
por: Bjerrum, Ole Weis, et al.
Publicado: (2019)

Myeloproliferative blood cancers as a human neuroinflammation model for development of Alzheimer’s disease: evidences and perspectives
por: Hasselbalch, Hans C., et al.
Publicado: (2020)

High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals
por: Holmström, Morten O., et al.
Publicado: (2019)

Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment
por: Kjær, Lasse, et al.
Publicado: (2016)

The Role of Reactive Oxygen Species in Myelofibrosis and Related Neoplasms
por: Bjørn, Mads Emil, et al.
Publicado: (2015)

P1047: REAL-WORLD SAFETY OF RUXOLITINIB IN PATIENTS WITH INTERMEDIATE OR HIGH RISK OF PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS IN CHINA
por: Xu, Z., et al.
Publicado: (2022)

Dermatomyositis Associated with Myelofibrosis following Polycythemia Vera
por: Fei, Naomi, et al.
Publicado: (2017)

A nationwide population-based cross-sectional survey of health-related quality of life in patients with myeloproliferative neoplasms in Denmark (MPNhealthSurvey): survey design and characteristics of respondents and nonrespondents
por: Brochmann, Nana, et al.
Publicado: (2017)

Tuberculosis Peritonitis During Treatment of Polycythemia Vera with Ruxolitinib
por: Sakiyama, Emiko, et al.
Publicado: (2020)

Ruxolitinib for myelofibrosis
por: GU, LIAN, et al.
Publicado: (2013)

The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation
por: Ikeda, Kazuhiko, et al.
Publicado: (2017)

A remarkable hematological and molecular response pattern in a patient with polycythemia vera during combination therapy with simvastatin and alendronate
por: Sørensen, Anders Lindholm, et al.
Publicado: (2016)

Ruxolitinib in the treatment of polycythemia vera: patient selection and special considerations
por: Blum, Sabine, et al.
Publicado: (2016)

Ruxolitinib: a targeted treatment option for patients with polycythemia vera
por: Vaddi, Kris, et al.
Publicado: (2016)

Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies
por: Sekhri, Rohit, et al.
Publicado: (2021)

The Copenhagen Primary Care Differential Count (CopDiff) database
por: Andersen, Christen Lykkegaard, et al.
Publicado: (2014)

Rapidly progressed aortic stenosis in a patient with previous diagnosis of polycythemia vera and post‐polycythemia vera myelofibrosis
por: Kiso, Shohei, et al.
Publicado: (2016)

The importance of cytogenetics in polycythemia vera, primary myelofibrosis and essential thrombocythemia
por: Conchon, Monika
Publicado: (2011)

Progression of primary myelofibrosis to polycythemia vera: A case report
por: Guo, Yan, et al.
Publicado: (2017)

Anxiety and depression in patients with Philadelphia-negative myeloproliferative neoplasms: a nationwide population-based survey in Denmark
por: Brochmann, Nana, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_r5e62kigrti6k7np9vpuh8cttv